Ustekinumab for chronic plaque psoriasis (Q81295694)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486724%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

title

Ustekinumab for chronic plaque psoriasis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486724%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

Brenda L Bartlett

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486724%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Stephen K Tyring

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486724%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

language of work or name

English

0 references

publication date

1 May 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486724%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486724%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

371

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486724%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

9625

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486724%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

1639-1640

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486724%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

cites work

Psoriasis comorbidities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960702-3

7 January 2021

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960702-3

7 January 2021

Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960702-3

7 January 2021

Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960702-3

7 January 2021

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960702-3

7 January 2021

The role of interleukin-12 in the pathogenesis of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960702-3

7 January 2021

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960702-3

7 January 2021

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960702-3

7 January 2021

Interleukin-12: biological properties and clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960702-3

7 January 2021

Natural killer cell mediated cytotoxicity of tumor cells initiated by neem leaf preparation is associated with CD40-CD40L-mediated endogenous production of interleukin-12.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960702-3

7 January 2021

IL-12, but not IL-18, is critical to neutrophil activation and resistance to polymicrobial sepsis induced by cecal ligation and puncture

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960702-3

7 January 2021

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960702-3

7 January 2021

10.1016/S0140-6736(08)60702-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486724%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486724%20AND%20SRC:MED&resulttype=core&format=json